Sividon Diagnostics GmbH – Trademark Portfolio

Entity Type: 16

Sividon Diagnostics GmbH holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ENDOPREDICT. The owner is based in Cologne.

Nattermannallee 1

S19

Cologne 50829 , DE

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Sividon Diagnostics GmbH's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does Sividon Diagnostics GmbH have?

Sividon Diagnostics GmbH has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does Sividon Diagnostics GmbH file in?

Sividon Diagnostics GmbH files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Sividon Diagnostics GmbH's most well-known trademarks?

Sividon Diagnostics GmbH's registered trademark portfolio includes well-known marks such as ENDOPREDICT. These are among 1 currently registered trademark in the portfolio.

What is Sividon Diagnostics GmbH's trademark registration success rate?

Sividon Diagnostics GmbH has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.